Dizziness

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Thursday, October 21, 2021 - 1:30pm

In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.

Key Points: 
  • In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.
  • Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a Phase 3, randomized, controlled superiority trial (VANISH-303) The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of oral ibrexafungerp for the treatment of VVC, also known as vaginal yeast infection.
  • Symptom resolution was sustained and further increased with ibrexafungerp compared with placebo (59.6% [112/188] vs 44.9% [44/98]; P=0.009) at follow-up.
  • Vulvovaginal Candidiasis (VVC), commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis.

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

Wednesday, October 20, 2021 - 12:00pm

"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.

Key Points: 
  • "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
  • RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
  • The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
  • Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.

Advisory - Ivermectin not authorized to prevent or treat COVID-19; may cause serious health problems

Tuesday, October 19, 2021 - 11:36pm

Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19.

Key Points: 
  • Health Canada is reminding Canadians not to use ivermectin to prevent or treat COVID-19.
  • There is no evidence that ivermectin works to prevent or treat COVID-19, and it is not authorized for this use.
  • Health Canada has received concerning reports of the use of veterinary ivermectin to prevent or treat COVID-19.
  • In this light, Health Canada is advising Canadians not to use either the veterinary or human drug versions of ivermectin to prevent or treat COVID-19.

Advisory - Ombrelle Garnier Complete Dry Mist Spray sunscreen recalled due to elevated benzene levels

Friday, October 15, 2021 - 11:05pm

Product:Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF 30 and SPF 60 (DIN02415313 and DIN 02415402)

Key Points: 
  • Product:Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF 30 and SPF 60 (DIN02415313 and DIN 02415402)
    Issue:Ombrelle Canada is recalling all lotsdue to elevated levels of benzene, which may pose serious health risks.
  • Ombrelle Canada is recalling all lots of Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF30 and SPF 60, due to elevated levels of benzene.
  • Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks.
  • Immediate signs of exposure to elevated levels of benzene include drowsiness, dizziness, rapid or irregular heartbeat, and headaches.

1 in 6 People Worldwide Struggles to Read Due to Irlen Syndrome

Thursday, October 14, 2021 - 1:24pm

While approximately half of those with this condition acquire it genetically, it can also be caused by brain injuries, high fevers, and viruses.

Key Points: 
  • While approximately half of those with this condition acquire it genetically, it can also be caused by brain injuries, high fevers, and viruses.
  • Children who are poor readers or poor in sports are often teased or bullied, resulting in feelings of shame or low self-worth.
  • In the Forward, Founder and Director of the Irlen Institute , Helen L. Irlen, explains the discovery of Irlen Syndrome and the progress made in treating it.
  • Author Catherine Matthias is a Certified Irlen Syndrome Screener and published author of six early reader picture books.

1 in 6 People Worldwide Struggles to Read Due to Irlen Syndrome

Thursday, October 14, 2021 - 8:24am

While approximately half of those with this condition acquire it genetically, it can also be caused by brain injuries, high fevers, and viruses.

Key Points: 
  • While approximately half of those with this condition acquire it genetically, it can also be caused by brain injuries, high fevers, and viruses.
  • In the Forward, Founder and Director of the Irlen Institute , Helen L. Irlen, explains the discovery of Irlen Syndrome and the progress made in treating it.
  • The Library Journal review concludes: "VERDICT: A helpful volume for parents, caregivers, and teachers of children who struggle with reading."
  • Author Catherine Matthias is a Certified Irlen Syndrome Screener and published author of six early reader picture books.

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Wednesday, October 13, 2021 - 1:30pm

We are deeply committed to innovation in the field of womens health and are extremely pleased to be able to share this additional pooled data analysis from our groundbreaking VANISH clinical research.

Key Points: 
  • We are deeply committed to innovation in the field of womens health and are extremely pleased to be able to share this additional pooled data analysis from our groundbreaking VANISH clinical research.
  • 24th Annual NPWH Premier Womens Healthcare Conference, October 13-16, 2021
    Title: BREXAFEMME (ibrexafungerp tablets) A Novel, Oral Treatment for Vulvovaginal Candidiasis
    Title: Efficacy and Safety of Oral Ibrexafungerp in Subjects with Vulvovaginal Candidiasis: Pooled Data from Two Phase 3, Randomized, Blinded, Study vs.
  • Meeting attendees can view the conference sessions and posters on demand until January 12, 2022.
  • In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Allergy & ENT Associates to Become First Texas User Of KUDUwave Portable Audiometer, Same Used by NASA

Tuesday, October 12, 2021 - 2:00pm

ABOUT ALLERGY & ENT ASSOCIATES:Established in 1957, Allergy & ENT Associates is the largest multi-specialty Allergy, Asthma, ENT, and Audiology group practice in the Houston area.

Key Points: 
  • ABOUT ALLERGY & ENT ASSOCIATES:Established in 1957, Allergy & ENT Associates is the largest multi-specialty Allergy, Asthma, ENT, and Audiology group practice in the Houston area.
  • Now with 16 locations, Allergy & ENT Associates provides trusted, attentive, and individualized care for allergy, asthma, audiology, and ENT services.
  • SPECIFICS:Allergy & ENT Associates becomes the first face-paced, diagnostic ENT/Audiology setting in Texas to use the KUDUwave Pro TMP, diagnostic immittance audiometer.
  • To request one of our American Board of Audiology Certified Audiologists, Board-certified Allergist/Immunologist, or ENT surgeon from Allergy & ENT Associates for appearances, interviews, or quotes:

Speed of Need Cleaning Air Duct Cleaning Services Helps Homeowners Prepare for the Holidays

Monday, October 11, 2021 - 1:47pm

ATLANTA, Oct. 11, 2021 /PRNewswire/ --Speed of Need Cleaning is helping homeowners across Atlanta get ready for the holiday season by providing Air Duct Cleaning services.

Key Points: 
  • ATLANTA, Oct. 11, 2021 /PRNewswire/ --Speed of Need Cleaning is helping homeowners across Atlanta get ready for the holiday season by providing Air Duct Cleaning services.
  • The goal of Air Duct Cleaning is to improve air quality, which reduces allergens and helps get rid of unpleasant odors in your home.
  • Many homeowners experience the benefits of Air Duct Cleaning immediately and can tell the difference in indoor air quality after Speed of Need Cleaning completes Air Duct Cleaning.
  • Speed of Need Cleaning is a second-generation, family-owned business that provides Air Duct Cleaning, pressure washing, and dryer vent cleaning services.

Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD® in Canada

Friday, October 8, 2021 - 3:30pm

BUFFALO GROVE, Ill., Oct. 8, 2021 /PRNewswire/ -- Tolmar, a specialty pharmaceutical company, today announced that, effective January 1, 2022, the company will hold exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in Canada. ELIGARD® is a prescription medication for the palliative treatment of advanced prostate cancer.

Key Points: 
  • With the establishment of Tolmar Pharmaceuticals Canada, Tolmar will resume the rights to ELIGARD in the Canadian market.
  • Tolmar will exclusively market, sell, and distribute ELIGARD in Canada after those respective dates.
  • "We are excited to regain the sales and marketing rights for ELIGARDin Canada," said Anil D'souza, CEO of Tolmar Pharmaceuticals.
  • The establishment of Tolmar Pharmaceuticals Canada will allow Tolmar to continue to advance ELIGARDinto the future."